Who
Inge G. Thulin
Director
Company insider
Files Form 4 as: Director, Merck & Company; Director, Chevron; Exec Chairman, 3m; Director, Toro.
In numbers
- Trades disclosed
- 828
- Buys
- 2
- Sells
- 31
- Bought
- $300K
- Sold
- $71.5M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 9 May 2006
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,853.1 at $118.72 | filing |
| 29 May 2026filed 2 Jun 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,853.1 at $118.72 | filing |
| 30 May 2025filed 3 Jun 2025 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K2,863.09 at $76.84 | filing |
| 6 Feb 2025filed 7 Feb 2025 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Bought | $250K2,832.86 at $88.25 | filing |
| 31 May 2024filed 4 Jun 2024 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,752.43 at $125.54 | filing |
| 26 May 2023filed 31 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,980.73 at $111.07 | filing |
| 27 May 2022filed 1 Jun 2022 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K2,363.56 at $93.08 | filing |
| 28 May 2021filed 2 Jun 2021 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K2,635.39 at $75.89 | filing |
| 29 May 2020filed 2 Jun 2020 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K2,477.7 at $80.72 | filing |
| 31 May 2019filed 4 Jun 2019 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $185K2,335.56 at $79.21 | filing |
| 29 May 2019filed 31 May 2019 | CVX ChevronIntegrated Oil Majors | SEC FORM 4 Code A | —1,901 at $0.00 | filing |
| 29 Mar 2019filed 2 Apr 2019 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $29K345.68 at $83.17 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $1,2506 at $208.28 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $21K100 at $208.45 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $21K100 at $208.49 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $21K100 at $208.51 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $21K100 at $208.53 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $42K200 at $208.67 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $31K150 at $208.80 | filing |
| 29 Mar 2019filed 1 Apr 2019 | MMM 3mDiversified Industrials | SEC FORM 4 Sold | $10K50 at $208.81 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Chevron looks to shed some ageing US Gulf assetsCVX · upstreamonline.com · 22 Oct 2026Delta community shuts Chevron oil wells over marginalisationCVX · punchng.com · 22 Oct 2026Chevron (NYSE:CVX) Stock: Insider R. Hewitt Pate Sells 40,700 SharesCVX · dailypolitical.com · 21 Oct 2026Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026Contrasting Merck & Co., Inc. (NYSE:MRK) and ABVC BioPharma (NASDAQ:ABVC)MRK · themarketsdaily.com · 21 Oct 20263M raises 2026 EPS guidance to $9.10-$9.15 while outlining $6B Amazon-linked data center sales milestones (NYSE:MMM)MMM · seekingalpha.com · 20 Oct 2026Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff?MRK · insidermonkey.com · 20 Oct 2026FinancialContent - 3M (NYSE:MMM) Reports Q3 2026 In Line With ExpectationsMMM · financialcontent.com · 20 Oct 2026
0 headlines in the last 90 days name Inge G. Thulin; 8 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.